GLIPR1L1抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human testis tissue, Primary antibody: P02214(GLIPR1L1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 15 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P02214(GLIPR1L1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

GLIPR1L1 (Glioma Pathogenesis-Related Protein 1-Like 1) is a member of the GLIPR protein family, which shares structural homology with pathogenesis-related (PR) proteins. Initially identified through genomic studies, GLIPR1L1 is characterized by a conserved CAP (cysteine-rich secretory protein, antigen 5. and pathogenesis-related 1) domain, suggesting roles in cell adhesion, signaling, or extracellular interactions. While its exact biological functions remain under investigation, GLIPR1L1 is implicated in cancer biology, particularly in prostate and bladder cancers, where altered expression patterns have been observed. It may influence tumor progression through mechanisms involving cell proliferation, apoptosis, or immune modulation.

Antibodies targeting GLIPR1L1 are critical tools for exploring its expression, localization, and functional roles in both normal and pathological contexts. These antibodies enable detection via techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence, aiding in biomarker discovery and validation. Emerging studies suggest GLIPR1L1's potential as a therapeutic target or diagnostic marker, driving interest in developing high-specificity antibodies. However, research remains preliminary, with challenges including limited epitope characterization and tissue-specific expression validation. Continued efforts focus on optimizing antibody reliability for translational applications in oncology and molecular pathology.